Literature DB >> 25034713

High prevalence of atrial fibrillation among patients with ischemic stroke.

Leif Friberg1, Mårten Rosenqvist2, Arne Lindgren2, Andreas Terént2, Bo Norrving2, Kjell Asplund2.   

Abstract

BACKGROUND AND
PURPOSE: Atrial fibrillation (AF) is a common cause of devastating but potentially preventable stroke. Estimates of the prevalence of AF among patients with stroke vary considerably because of difficulties in detection of intermittent, silent AF. Better recognition of AF in this patient group may help to identify and offer protection to individuals at risk. Our aim was to determine the nationwide prevalence of AF among patients with ischemic stroke, as well as their use of oral anticoagulation.
METHODS: Cross-sectional study of unselected patients in cross-linked nationwide Swedish health registers. All 94 083 patients with a diagnosis of ischemic stroke in the nationwide stroke register Riks-Stroke between 2005 and 2010 were studied. Information about previously diagnosed AF, and comorbidity, was obtained from the nationwide Patient Register and cross-referenced with the national Drug Register containing data on all dispensed pharmacological prescriptions in Sweden.
RESULTS: Combination of data from Riks-Stroke and from the Patient Register showed that 31 428 (33.4%) patients with ischemic stroke had previously known, or newly diagnosed, AF. Of those, only 16.2% had received warfarin in a pharmacy within 6 months before stroke onset. After hospital discharge, only 35.0% of the survivors received warfarin within the first 3 months after discharge. The likelihood for underlying AF was strongly correlated to the CHA2DS2-VASC score, which is a point based scheme for assessment of stroke risk in AF but which also predicts likelihood of AF. In this scheme points are given for age, previous stroke or transient ischemic attack, hypertension, heart failure, diabetes, vascular disease and female sex.
CONCLUSIONS: Access to nationwide register data shows that AF is more common among patients with ischemic stroke than those previously reported. Few patients with stroke and AF had anticoagulant treatment before the event, and few got it after the event. CHA2DS2-VASc could be a useful monitoring tool to intensify efforts to diagnose AF among patients with cryptogenic stroke.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  atrial fibrillation; stroke

Mesh:

Substances:

Year:  2014        PMID: 25034713     DOI: 10.1161/STROKEAHA.114.006070

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  66 in total

Review 1.  Management of Embolic Stroke of Undetermined Source (ESUS).

Authors:  Tobias Geisler; Annerose Mengel; Ulf Ziemann; Sven Poli
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

2.  The gap between indicated and prescribed stroke prevention therapies in a high-risk geriatric population.

Authors:  Mohammed Shurrab; Eugene Crystal; Denis O'Donnell; Hrishikesh Navare; Paula Neves; Rasha Khatib; Ilan Lashevsky; David Newman
Journal:  J Interv Card Electrophysiol       Date:  2017-01-16       Impact factor: 1.900

Review 3.  Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation.

Authors:  Fahad Shaikh; Lachlan B Pasch; Phillip J Newton; Beata V Bajorek; Caleb Ferguson
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

4.  Age-and-sex stratified prevalence of atrial fibrillation in rural Western India: Results of SMART-India, a population-based screening study.

Authors:  Apurv Soni; Sunil Karna; Nisha Fahey; Saket Sanghai; Harshil Patel; Shyamsundar Raithatha; Sunil Thanvi; Somashekhar Nimbalkar; Ben Freedman; Jeroan Allison; David D McManus
Journal:  Int J Cardiol       Date:  2018-12-06       Impact factor: 4.164

5.  Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study.

Authors:  Sergio Conti; James A Reiffel; Bernard J Gersh; Peter R Kowey; Rolf Wachter; Jonathan L Halperin; Rachelle E Kaplon; Erika Pouliot; Atul Verma
Journal:  J Atr Fibrillation       Date:  2017-02-28

6.  2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society.

Authors:  Niraj Varma; Iwona Cygankiewicz; Mintu P Turakhia; Hein Heidbuchel; Yu-Feng Hu; Lin Yee Chen; Jean-Philippe Couderc; Edmond M Cronin; Jerry D Estep; Lars Grieten; Deirdre A Lane; Reena Mehra; Alex Page; Rod Passman; Jonathan P Piccini; Ewa Piotrowicz; Ryszard Piotrowicz; Pyotr G Platonov; Antonio Luiz Ribeiro; Robert E Rich; Andrea M Russo; David Slotwiner; Jonathan S Steinberg; Emma Svennberg
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-02-12

7.  Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke.

Authors:  Emer R McGrath; Alan S Go; Yuchiao Chang; Leila H Borowsky; Margaret C Fang; Kristi Reynolds; Daniel E Singer
Journal:  J Am Geriatr Soc       Date:  2016-12-30       Impact factor: 5.562

8.  Anticoagulation and population risk of stroke and death in incident atrial fibrillation: a population-based cohort study.

Authors:  Amy Y X Yu; Shaun Malo; Stephen Wilton; Ratika Parkash; Lawrence W Svenson; Michael D Hill
Journal:  CMAJ Open       Date:  2016-01-07

9.  Systematic Screening for Atrial Fibrillation in the Community: Evidence and Obstacles.

Authors:  Ngai-Yin Chan
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-03

10.  Performance of an atrial fibrillation detection algorithm using continuous pulse wave monitoring.

Authors:  Asami Kashiwa; Fumio Koyama; Koji Miyamoto; Tsukasa Kamakura; Mitsuru Wada; Kenichiro Yamagata; Kohei Ishibashi; Yuko Inoue; Hideo Okamura; Satoshi Nagase; Takashi Noda; Takeshi Aiba; Shinichiro Watanabe; Akihiro Goto; Satoshi Yasuda; Kengo Kusano
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-11-02       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.